The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Abstract
Purpose: The objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy. Patients and Methods: Women ≥ 18 years, stratified by performance status (0 to 1 v 2) and platinum sensitivity, were randomly assigned to receive an intravenous infusion of PLD 30 mg/m 2 followed by a 3-hour infusion of trabectedin 1.1 mg/m 2 every 3 weeks or PLD 50 mg/m 2 every 4 weeks. The primary end point was progression-free survival (PFS) by independent radiology assessment. Results: Patients (N = 672) were randomly assigned to trabectedin/PLD (n = 337) or PLD (n = 335). Median PFS was 7.3 months with trabectedin/PLD v 5.8 months with PLD (hazard ratio, 0.79; 95% CI, 0.65 to 0.96; P = .0190). For platinum-sensitive patients, median PFS was 9.2 months v 7.5 months, respectively (hazard ratio, 0.73; 95% CI, 0.56 to 0.95; P = .0170). Overall response rate (ORR) was 27.6% for trabectedin/PLD v 18.8% for PLD (P = .0080); for platinum-sensitive patients, it was 35.3% v 22.6% (P = .0042), respectively. ORR, PFS, and overall survival among platinum-resistant patients were not statistically different. Neutropenia was more common with trabectedin/PLD. Grade 3 to 4 transaminase elevations were also more common with the combination but were transient and noncumulative. Hand-foot syndrome and mucositis were less frequent with trabectedin/PLD than with PLD alone. Conclusion: When combined with PLD, trabectedin improves PFS and ORR over PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Gordon, A. N., Fleagle, J., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, Á. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,212
Flagged first, then by citations
Research works printed but not linked: 2
- Takahashi N, 2001, Clin Cancer Res, 7, 3251
- Donald S, 2003, Cancer Res, 63, 5902
Cited by
Sorted by citations
Items 101–200 of 395
A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma
Vergote, I. B., Smith, D. C., Berger, R., Kurzrock, R., Vogelzang, N. J., Sella, A., Wheler, J. J., Lee, Y., Foster, P., Weitzman, R., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.018 · Cited by 34
Self-citationGadducci, A., & Cosio, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.914342 · Cited by 34
Tamura, R., Yokoyama, Y., Yoshida, H., Imaizumi, T., & Mizunuma, H. (2014) · Journal of Ovarian Research · doi:10.1186/preaccept-4117485191398206 · Cited by 34
Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough?
Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7077 · Cited by 34
Wong, K., Mang, O. W. K., Au, K., & Law, S. C. K. (2012) · PubMed · Cited by 33
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Yuan, Z., Zhang, Y., Cao, D., Shen, K., Li, Q., Zhang, G., Wu, X., Cui, M., Yue, Y., Cheng, W., et al. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-020-00736-2 · Cited by 33
Self-citationCampo, J. M. D., Sessa, C., Krasner, C. N., Vermorken, J. B., Colombo, N., Kaye, S. B., Gore, M. E., Zintl, P., Gómez, J., Parekh, T. V., et al. (2013) · Medical Oncology · doi:10.1007/s12032-012-0435-1 · Cited by 32
Self-citationTomao, F., Marchetti, C., Romito, A., Pinto, A. D., Donato, V. D., Capri, O., Palaia, I., Monti, M., Muzii, L., & Panici, P. B. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1328055 · Cited by 32
Recurrent Ovarian Cancer: When and How to Treat
Hall, M., & Rustin, G. J. S. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0199-3 · Cited by 32
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine
Muggia, F. M., Diaz, I., & Peters, G. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.666236 · Cited by 32
Self-citationOverview of a chemoresponse assay in ovarian cancer
Grendys, E. C., Fiorica, J. V., Orr, J. W., Holloway, R. W., Wang, D., Tian, C., Chan, J. K., & Herzog, T. J. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1192-8 · Cited by 31
Self-citationSmall molecule drugs – optimizing DNA damaging agent-based therapeutics
Hartley, J. A., & Hochhauser, D. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.03.008 · Cited by 31
Massutí, B., Cobo, M., Camps, C., Dómine, M., Provencio, M., Alberola, V., Viñolas, N., Rosell, R., Tarón, M., Gutiérrez, V., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.002 · Cited by 31
Wolford, J. E., Bai, J., Moore, K. N., Kristeleit, R. S., Monk, B. J., & Tewari, K. S. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.02.030 · Cited by 31
Self-citationMarkman, M. M. (2011) · Cancer Management and Research · doi:10.2147/cmar.s15558 · Cited by 31
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options
Elit, L. M., & Hirte, H. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s30238 · Cited by 30
Grosso, F., D’Incalci, M., Cartoafa, M., Nieto, A., Fernández‐Teruel, C., Alfaro, V., Lardelli, P., Roy, E., Gómez, J., Kahatt, C. M., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1864-4 · Cited by 29
van der Burg, M. E. L., Vergote, I. B., Onstenk, W., Boere, I. A., Leunen, K., van Montfort, C. A. G. M., & van Doorn, H. C. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.027 · Cited by 28
Self-citationClinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer
Ledermann, J. A., & Raja, F. A. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70154-x · Cited by 27
Advances in Multidisciplinary Management of Skull Base Meningiomas
Ius, T., Tel, A., Minniti, G. C., Somma, T., Solari, D., Longhi, M., BONIS, P. D., Scerrati, A., Caccese, M., Barresi, V., et al. (2021) · Cancers · doi:10.3390/cancers13112664 · Cited by 27
Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Maenpaa, J. U., Sessa, C., Montes, A., Ottevanger, N. P. B., Berger, R., Vergote, I. B., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02108-7 · Cited by 27
Self-citationSehouli, J., Alfaro, V., & González-Martı́n, A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr321 · Cited by 27
Systemic therapy for recurrent meningioma
Rhun, É. L., Taillibert, S., & Chamberlain, M. C. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1184087 · Cited by 27
Zhang, J., Zhang, Y., Tang, S., Jiang, L., He, Q., Hamblin, L. T., He, J., Wu, J., Wu, J., Chen, Y., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017240 · Cited by 27
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis
Lebedinsky, C. A., Gómez, J., Park, Y. C., Nieto, A., Soto-Matos, A., Parekh, T. V., Alfaro, V., Roy, E., Lardelli, P., & Kahatt, C. M. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1614-z · Cited by 27
Self-citationHerzog, T. J., Vermorken, J. B., Pujade-Lauraine, É., Provencher, D. M., Jagiełło-Gruszfeld, A., Kong, B., Boman, K., Park, Y. C., Parekh, T. V., Lebedinsky, C. A., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.04.005 · Cited by 26
Self-citationNew emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer
Brüning, A., & Mylonas, I. G. (2010) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-010-1757-x · Cited by 26
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines
Avila, S., Núñez, G. S., García‐Fernández, L., & Galmarini, C. M. (2015) · Journal of Breast Cancer · doi:10.4048/jbc.2015.18.4.329 · Cited by 26
Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer
Raghavan, R., Hyter, S. D., Pathak, H. B., Godwin, A. K., Konecny, G. E., Wang, C., Goode, E. L., & Fridley, B. L. (2016) · BMC Genomics · doi:10.1186/s12864-016-3149-5 · Cited by 26
RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas
Obrador-Hevia, A., Martinez-Font, E., Felipe-Abrio, I., Calabuig-Fariñas, S., Serra-Sitjar, M., López-Guerrero, J. A., Ramos, R., Alemany, R., & Martín-Broto, J. (2015) · Cancer Investigation · doi:10.3109/07357907.2015.1064534 · Cited by 24
Trabectedin in Cancers: Mechanisms and Clinical Applications
Wang, J., Wang, P., Zeng, Z., Lin, C., Lin, Y., Cao, D., Ma, W., Xu, W., Xiang, Q., Luo, L., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220526125806 · Cited by 25
Aghajanian, C. A., Goff, B. A., Nycum, L. R., Wang, Y. V., Husain, A., & Blank, S. V. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.003 · Cited by 24
Uboldi, S., Bernasconi, S., Romano, M., Marchini, S., Nerini, I. F., Damia, G. L. M., Ganzinelli, M., Marangon, E., Sala, F., Clivio, L., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26340 · Cited by 24
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters
Martella, F., Salutari, V., Marchetti, C., Pisano, C., Napoli, M. D., Pietta, F., Centineo, D., Caringella, A. M., Musella, A., & Fioretto, L. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000275 · Cited by 24
Update of randomized trials in recurrent disease
Pujade-Lauraine, É., & Alexandre, J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr518 · Cited by 24
Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
Berek, J. S., Friedlander, M. L., & Bast, R. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm105 · Cited by 25
Poonawalla, I. B., Parikh, R. C., Du, X. L., VonVille, H. M., & Lairson, D. R. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0304-9 · Cited by 23
Efficacy of trabectedin in metastatic solitary fibrous tumor
Chaigneau, L., Kalbacher, E., Thiery-Vuillemin, A., Fagnoni-Legat, C., Isambert, N., Aherfi, L., Pauchot, J., Delroeux, D., Servagi-Vernat, S., Mansi, L., et al. (2011) · Rare Tumors · doi:10.4081/rt.2011.e29 · Cited by 23
How to approach patients in relapse
Pujade-Lauraine, É. (2012) · Annals of Oncology · doi:10.1093/annonc/mds358 · Cited by 23
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cance
López‐Guerrero, J. A., Romero, I., & Poveda, A. M. (2015) · 癌症：英文版 · doi:10.5732/cjc.014.10278 · Cited by 23
Self-citationZhu, X., & Lang, J. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.002 · Cited by 23
Chuang, Y.-T., & Chang, C. (2012) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2012.07.003 · Cited by 22
Treatment algorithm in patients with ovarian cancer.
Vergote, I. B., Denys, H. G., Grève, J. D., Gennigens, C., de Vijver, K. K. V., Kerger, J. N., Vuylsteke, P., & Baurain, J. F. (2020) · PubMed Central · Cited by 22
Self-citationParma, G., Mancari, R., Conte, G. D., Scambia, G., Gadducci, A., Hess, D., Katsaros, D., Sessa, C., Rinaldi, A., Bertoni, F., et al. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e318251051a · Cited by 21
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
Romano, M., Porta, M. G. D., Gallì, A., Panini, N., Licandro, S. A., Bello, E., Craparotta, I., Rosti, V., Bonetti, E., Tancredi, R. J., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.424 · Cited by 21
for the Japanese Gynecologic Oncology Group, Shoji, T., Komiyama, S., Kigawa, J., Tanabe, H., Kato, K., Itamochi, H., Fujiwara, H., Kamiura, S., Hamano, T., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4505-4 · Cited by 21
Trabectedin: Supportive care strategies and safety profile
Jordan, K., Jahn, F., Jordan, B., Kegel, T., Müller‐Tidow, C., & Rüssel, J. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.02.012 · Cited by 21
Efficacy of Trabectedin in Platinum-Sensitive-Relapsed Ovarian Cancer
Colombo, N. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e318217b321 · Cited by 20
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
Newhouse, R., Nelissen, E., El-Shakankery, K. H., Rogozińska, E., Bain, E., Veiga, S., & Morrison, J. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006910.pub3 · Cited by 20
Salmaninejad, A., Layeghi, S. M., Falakian, Z., Golestani, S., Kobravi, S., Talebi, S., & Yousefi, M. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01417-w · Cited by 22
Ferrandina, G., Salutari, V., Vincenzi, B., Marinaccio, M., Naglieri, E., Loizzi, V., Carpano, S., Amadio, G., Tonini, G., Scambia, G., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.06.008 · Cited by 20
Trabectedin: Safety and Efficacy in the Treatment of Advanced Sarcoma
Gajdos, C., & ELIAS, A. D. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s4907 · Cited by 20
Pignata, S., Scambia, G., Villanucci, A., Naglieri, E., Ibarbia, M. A., Brusa, F., Bourgeois, H. P., Sorio, R., Casado, A., Reichert, D. A., et al. (2020) · The Oncologist · doi:10.1002/onco.13630 · Cited by 20
Pacifico, F., Mellone, S., D’Incalci, M., Stornaiuolo, M., Leonardi, A., & Crescenzi, E. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115159 · Cited by 20
Therapeutic strategies for targeting the ovarian tumor stroma
Ko, S. Y., & Naora, H. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i6.194 · Cited by 20
Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
Berek, J. S., Renz, M., Friedlander, M. L., & Bast, R. C. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm105.pub2 · Cited by 20
Optimizing Treatment of the Partially Platinum-Sensitive Ovarian Cancer Patient
Colombo, N. (2013) · Future Oncology · doi:10.2217/fon.13.206 · Cited by 19
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives
Matsumoto, K., Onda, T., & Yaegashi, N. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv014 · Cited by 20
A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer
Krivak, T. C., Lele, S., Richard, S. D., Secord, A. A., Leath, C. A., Brower, S. L., Tian, C., & Moore, R. G. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.02.009 · Cited by 19
Salvatorelli, E., Tursi, M. D., Menna, P., Carella, C., Massari, R., Colasante, A., Iacobelli, S., & Minotti, G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.047480 · Cited by 19
Schuller, Y., Biegstraaten, M., Hollak, C. E. M., Klümpen, H., Wied, C. C. G., & Stoyanova-Beninska, V. V. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0900-9 · Cited by 19
Trabectedin in Ovarian Cancer: is it now a Standard of Care?
Ventriglia, J., Paciolla, I., Cecere, S. C., Pisano, C., Napoli, M. D., Arenare, L., Setola, S. V., Losito, S., Califano, D., Orditura, M., et al. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.01.008 · Cited by 19
Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient
Colombo, N. (2014) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(15)70004-2 · Cited by 18
Major clinical research advances in gynecologic cancer in 2010
Suh, D. H., Kim, J., Kim, K., & Kang, S. (2010) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2010.21.4.209 · Cited by 18
Antitumor Therapy Targeting the Tumor Microenvironment
Gao, Y., Pan, Z., Li, H., & Wang, F. (2023) · Journal of Oncology · doi:10.1155/2023/6886135 · Cited by 19
Ovarian cancer: relevant therapy, not timing, is paramount
Morris, R. T., & Monk, B. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61515-2 · Cited by 18
Self-citationLeporini, C., Patanè, M., Saullo, F., Rende, P., Gallelli, L., Paola, E. D. D., Toscano, R., Lúcia, M., Rossi, M., Sarro, G. D., et al. (2014) · BioDrugs · doi:10.1007/s40259-014-0100-7 · Cited by 18
García, M. J., Saucedo-Cuevas, L. P., Muñoz‐Repeto, I., Fernández, V., Robles, M. J., Domingo, S., Palacios, J., Aracil, M., Nieto, A., Tercero, J. C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0768 · Cited by 18
Current and future strategies for treatment of ovarian clear cell carcinoma
Ogasawara, A., Sato, S., & Hasegawa, K. (2020) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14350 · Cited by 18
Revisiting Immune-Based Therapies for Aggressive Follicular Cell–Derived Thyroid Cancers
French, J. D. (2013) · Thyroid · doi:10.1089/thy.2012.0566 · Cited by 18
The efficacy of trabectedin in treating ovarian cancer
Teplinsky, E., & Herzog, T. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285282 · Cited by 18
Self-citationCamorani, S., Cerchia, L., Fedele, M., Erba, E., D’Incalci, M., & Crescenzi, E. (2018) · Oncotarget · doi:10.18632/oncotarget.24961 · Cited by 18
Naora, H. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00018 · Cited by 17
Goldstein, L. J., Gurtler, J., Prete, S. A. D., Tjulandin, S., Семиглазов, В. Ф., Bayever, E., & Michiels, B. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.06.006 · Cited by 17
Current status of bevacizumab in advanced ovarian cancer
Rossi, L., Tomao, F., Papa, A., Caruso, D., Panici, P. B., Tomao, F., & Venezia, M. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s46301 · Cited by 17
Bamias, A., Bamia, C., Zagouri, F., Kostouros, E., Kakoyianni, K., Rodolakis, A., Vlachos, G. D., Haidopoulos, D. A., Thomakos, N., Antsaklis, A. J., et al. (2012) · Oncology · doi:10.1159/000341366 · Cited by 17
Monk, B. J., Sill, M. W., Hanjani, P., Edwards, R. P., Rotmensch, J., Geest, K. D., Bonebrake, A. J., & Walker, J. L. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.11.012 · Cited by 17
Self-citationBevacizumab as First-Line Treatment in HER2-Negative Advanced Breast Cancer: Pros and Cons
Sini, V., Cassano, A., Corsi, D. C., Laurentiis, M. D., Gamucci, T., Mauri, M., Naso, G., Roselli, M., Ruggeri, E. M., Tonini, G., et al. (2016) · Tumori Journal · doi:10.5301/tj.5000555 · Cited by 17
Marine Ligands of the Pregnane X Receptor (PXR): An Overview
Carazo, A., Mladěnka, P., & Pávek, P. (2019) · Marine Drugs · doi:10.3390/md17100554 · Cited by 17
Recurrent High Grade Serous Ovarian Cancer Management
Luyckx, M., Squifflet, J.-L., Bruger, A. M., & Baurain, J. (2022) · Exon Publications eBooks · doi:10.36255/exon-publications-ovarian-cancer-management · Cited by 16
Sehouli, J., Tomé, O., Dimitrova, D., Camara, O., Runnebaum, I. B., Tessen, H. W., Rautenberg, B., Chekerov, R., Muallem, M. Z., Lux, M. P., et al. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2307-0 · Cited by 16
Englinger, B., Mair, M. J., Miklos, W., Pirker, C., Mohr, T. T., van Schoonhoven, S., Lötsch, D., Körner, W., Ferk, F., Knasmüller, S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.449 · Cited by 16
Pendlebury, A., Debernardo, R. L., & Rose, P. G. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000521 · Cited by 16
Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline
Francis, J., Coakley, N., Elit, L. M., & MacKay, H. J. (2017) · Current Oncology · doi:10.3747/co.24.3824 · Cited by 16
Rakowski, J. A., Ahmad, S., & Holloway, R. W. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.187 · Cited by 15
Sessa, C., Conte, G. D., Christinat, A., Cresta, S., Perotti, A., Gallerani, E., Lardelli, P., Kahatt, C. M., Alfaro, V., Iglesias, J. L., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9942-y · Cited by 15
Lorusso, D., Sabatucci, I., Maltese, G., Lepori, S., Tripodi, E., Bogani, G., & Raspagliesi, F. (2019) · Tumori Journal · doi:10.1177/0300891619839308 · Cited by 15
A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
Yu, J., Wang, N., & Kågedal, M. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12499 · Cited by 15
Sanctis, R. D., Jacobs, F., Benvenuti, C., Gaudio, M., Franceschini, R., Tancredi, R. J., Pedrazzoli, P., Santoro, A., & Zambelli, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.909566 · Cited by 15
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence
Ferrandina, G., Mascilini, F., Amadio, G., Stefano, M. G. D., Legge, A. D., Vincenzo, R. D., Masciullo, V., Salutari, V., Scambia, G., Conte, C., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s51550 · Cited by 15
Morotti, M., Menada, M. V., Venturini, P. L., & Ferrero, S. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.570330 · Cited by 15
Ricci, F., Guffanti, F., Damia, G. L. M., & Broggini, M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0662-3 · Cited by 15
Casado, A., Callata, H., Manzano, A., Marquina, G., Alonso, T., Gajate, P., Sotelo, M. J., Cabezas-Camarero, S., Fernández, C., & Díaz‐Rubio, E. (2018) · Future Oncology · doi:10.2217/fon-2018-0554 · Cited by 15
Zhang, J., Zhang, Y., Tang, S., Liang, H., Chen, D., Jiang, L., He, Q., Huang, Y., Wang, X., Deng, K., et al. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.24 · Cited by 15
Bevacizumab and Its Use in Epithelial Ovarian Cancer
Matulonis, U. A. (2011) · Future Oncology · doi:10.2217/fon.10.167 · Cited by 14
Phase II Study of Gemcitabine and Docetaxel in Recurrent Platinum Resistant Ovarian Cancer
García, A. A., Yessaian, A. A., Pham, H. Q., Facio, G., Muderspach, L. I., & Roman, L. D. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.657812 · Cited by 14
Takano, M., Ikeda, Y., Kudoh, K., Kita, T., Sasaki, N., & Kikuchi, Y. (2012) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2012.02047.x · Cited by 14
Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review
André, L., Antherieu, G., Boinet, A., Bret, J., Gilbert, T., Boulahssass, R., & Falandry, C. (2022) · Cancers · doi:10.3390/cancers14102470 · Cited by 14
González-Martı́n, A., Redondo, A., Jurado, M., Juan, A. D., Romero, I., Bover, I., del Campo, J. M., Cervantes, A. M. R., García, Y. G., López‐Guerrero, J. A., et al. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0995-8 · Cited by 14
Self-citationArmeni, P., Borsoi, L., Fornaro, G. A., Jommi, C., Colombo, N., & Costa, F. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.04.015 · Cited by 14
Metadata
- Authors
- Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., Gorbounova, V. A., Ghatage, P., Bidzinski, M., Shen, K., Ngan, H. Y.-S., Vergote, I. B., Nam, J.-H., Park, Y. C., Lebedinsky, C. A., & Poveda, A. M.
- Affiliations
- University of California, Irvine (US)
- From the University of California at Irvine (UCI) and UCI Medical Center, Orange, CA; Columbia University College of Physicians and Surgeons; New York University Hospital, New York, NY; the Royal Marsden Hospital, Surrey, United Kingdom; Gillette Center for Women's Studies, Massachusetts General Hospital, Boston, MA; Antwerp University Hospital, Edegem; University Hospital, Leuven, Belgium; Université Paris Descartes, Assistance Publique Hôpitaux de Paris, Hôpital Hôtel-Dieu, Paris, France; SPBSIH City...
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2010-07-01
- Volume
- 28
- Issue
- 19
- Pages
- 3107-3114
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2125064537
- Cited by
- 395
- References
- 30
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 9 · 2023: 10 · 2022: 17 · 2021: 25 · 2020: 18 · 2019: 13 · 2018: 25 · 2017: 41 · 2016: 26 · 2015: 32 · 2014: 37 · 2013: 40 · 2012: 37
- FWCI
- 51.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- trabectedin, pegylated liposomal doxorubicin, recurrent ovarian cancer, second-line chemotherapy, platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, progression-free survival, overall response rate, neutropenia, transaminase elevation, hand-foot syndrome, mucositis
- MeSH terms
- Trabectedin, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dioxoles, Doxorubicin, Drug Administration Schedule, Female, Humans, Leukopenia, Middle Aged, Neoplasm Recurrence, Local, Neutropenia, Ovarian Neoplasms, Polyethylene Glycols, Stomatitis, Multivariate Analysis, Treatment Outcome, Tetrahydroisoquinolines, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
